PAPER Heras-Garvin A, Weckbecker D, Ryazanov S, Leonov A, Griesinger C, Giese A, Wenning GK, Stefanova N
SEARCH RESULTS
16174 RESULTS
PAPER Ghazi Sherbaf F, Mohajer B, Ashraf-Ganjouei A, Mojtahed Zadeh M, Javinani A, Sanjari Moghaddam H, Shirin Shandiz M, Aarabi MH
Serum Insulin-Like Growth Factor-1 in Parkinson's Disease; Study of Cerebrospinal Fluid Biomarkers and White Matter Microstructure.
Front Endocrinol (Lausanne). 2018;9:608. Epub 2018 Nov 2 PubMed: 30450079PAPER Gautam M, Jara JH, Kocak N, Rylaarsdam LE, Kim KD, Bigio EH, Hande Özdinler P
Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology.
Acta Neuropathol. 2019 Jan;137(1):47-69. Epub 2018 Nov 19 PubMed: 30450515PAPER Tang S, Yao B, Li N, Lin S, Huang Z
Association of Dopamine Beta-Hydroxylase Polymorphisms with Alzheimer's Disease, Parkinson's Disease and Schizophrenia: Evidence Based on Currently Available Loci.
Cell Physiol Biochem. 2018;51(1):411-428. Epub 2018 Nov 19 PubMed: 30453293PAPER Hanko V, Apple AC, Alpert KI, Warren KN, Schneider JA, Arfanakis K, Bennett DA, Wang L
In vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies.
Neurobiol Aging. 2019 Feb;74:171-181. Epub 2018 Oct 25 PubMed: 30453234PAPER Zecca C, Brescia V, Panza F, Logroscino G
Response to Letter to the Editor: "Plasma β-amyloid1-42 reference values".
J Neurol Sci. 2019 Jan 15;396:123-124. Epub 2018 Nov 9 PubMed: 30453206PAPER Pradeepkiran JA, Reddy AP, Reddy PH
Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
Drug Discov Today. 2019 Feb;24(2):616-623. Epub 2018 Nov 16 PubMed: 30453058PAPER Lapresa R, Agulla J, Sánchez-Morán I, Zamarreño R, Prieto E, Bolaños JP, Almeida A
Amyloid-ß promotes neurotoxicity by Cdk5-induced p53 stabilization.
Neuropharmacology. 2019 Mar 1;146:19-27. Epub 2018 Nov 16 PubMed: 30452955PAPER Ilieva K, Tchekalarova J, Atanasova D, Kortenska L, Atanasova M
Antidepressant agomelatine attenuates behavioral deficits and concomitant pathology observed in streptozotocin-induced model of Alzheimer's disease in male rats.
Horm Behav. 2019 Jan;107:11-19. Epub 2018 Nov 22 PubMed: 30452900PAPER Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EM, Tybulewicz VL, Nizetic D, Strydom A
Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years.
JAMA Neurol. 2018 Nov 19; PubMed: 30452522PAPER Rafii MS, Santoro SL
Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome.
JAMA Neurol. 2018 Nov 19; PubMed: 30452497PAPER Okuya M, Matsunaga S, Ikuta T, Kishi T, Iwata N
Efficacy, Acceptability, and Safety of Intravenous Immunoglobulin Administration for Mild-To-Moderate Alzheimer's Disease: A Systematic Review and Meta-Analysis.
J Alzheimers Dis. 2018;66(4):1379-1387. PubMed: 30452419PAPER Koseoglu MM, Norambuena A, Sharlow ER, Lazo JS, Bloom GS
Aberrant Neuronal Cell Cycle Re-Entry: The Pathological Confluence of Alzheimer's Disease and Brain Insulin Resistance, and Its Relation to Cancer.
J Alzheimers Dis. 2019;67(1):1-11. PubMed: 30452418PAPER Francis PT, Costello H, Hayes GM
Brains for Dementia Research: Evolution in a Longitudinal Brain Donation Cohort to Maximize Current and Future Value.
J Alzheimers Dis. 2018;66(4):1635-1644. PubMed: 30452415PAPER Helman AM, Siever M, McCarty KL, Lott IT, Doran E, Abner EL, Schmitt FA, Head E
Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.
J Alzheimers Dis. 2019;67(1):103-112. PubMed: 30452414Current Filters
- Date Range : Nov 2018 to Nov 2019 x